1. Home
  2. FDUS vs ARVN Comparison

FDUS vs ARVN Comparison

Compare FDUS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fidus Investment Corporation

FDUS

Fidus Investment Corporation

HOLD

Current Price

$17.84

Market Cap

683.6M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$12.30

Market Cap

781.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FDUS
ARVN
Founded
2011
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
683.6M
781.0M
IPO Year
2011
2018

Fundamental Metrics

Financial Performance
Metric
FDUS
ARVN
Price
$17.84
$12.30
Analyst Decision
Buy
Buy
Analyst Count
3
21
Target Price
$21.17
$15.71
AVG Volume (30 Days)
267.4K
706.7K
Earning Date
05-29-2026
05-27-2026
Dividend Yield
12.05%
N/A
EPS Growth
N/A
58.84
EPS
2.08
N/A
Revenue
N/A
$262,600,000.00
Revenue This Year
$6.01
N/A
Revenue Next Year
$4.28
N/A
P/E Ratio
$8.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.41
$5.90
52 Week High
$22.09
$14.22

Technical Indicators

Market Signals
Indicator
FDUS
ARVN
Relative Strength Index (RSI) 40.91 42.75
Support Level $17.41 $11.07
Resistance Level $20.45 $12.62
Average True Range (ATR) 0.48 0.70
MACD -0.01 -0.13
Stochastic Oscillator 31.75 18.86

Price Performance

Historical Comparison
FDUS
ARVN

About FDUS Fidus Investment Corporation

Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Share on Social Networks: